Cost and cost-effectiveness of childhood vaccination against rotavirus in France.

[1]  G. Davidson,et al.  IMPORTANCE OF A NEW VIRUS IN ACUTE SPORADIC ENTERITIS IN CHILDREN , 1975, The Lancet.

[2]  Harry Greenberg,et al.  A Prospective Study of Rotavirus Infection in Infants and Young Children , 1981, The Journal of infectious diseases.

[3]  R. Kaslow,et al.  Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations , 1987, The Pediatric infectious disease journal.

[4]  G. Beards,et al.  Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period. , 1990, Scandinavian journal of infectious diseases.

[5]  T. Vesikari,et al.  Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. , 1990, Scandinavian journal of infectious diseases.

[6]  M. Rennels,et al.  An efficacy trial of the rhesus rotavirus vaccine in Maryland. The Clinical Study Group. , 1990, American journal of diseases of children.

[7]  G. Beards,et al.  Rhesus Rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age. , 1990, American journal of diseases of children.

[8]  T. Vesikari,et al.  A Prospective Study of Acute Diarrhoea in Finnish Children from Birth to 2 1/2 Years of Age , 1991, Acta paediatrica Scandinavica.

[9]  T. Vesikari,et al.  Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity. , 1992, The Pediatric infectious disease journal.

[10]  D. Bernstein,et al.  Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group. , 1994, The Journal of infectious diseases.

[11]  Erry,et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.

[12]  R. Glass,et al.  Evaluation of Rhesus Rotavirus Monovalent and Tetravalent Reassortant Vaccines in US Children , 1995 .

[13]  R. Glass,et al.  Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. , 1995, JAMA.

[14]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[15]  R. Brooks.  EuroQol: the current state of play. , 1996, Health policy.

[16]  B. Detournay,et al.  Cost-effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in France. , 1996, Vaccine.

[17]  R. Glass,et al.  Safety and Efficacy of High-dose Rhesus-Human Reassortant Rotavirus Vaccines-Report of the National Multicenter Trial , 1996, Pediatrics.

[18]  R. Glass,et al.  Rotavirus infection in infants as protection against subsequent infections. , 1996, The New England journal of medicine.

[19]  A. Martinot,et al.  Evaluation du traitement ambulatoire des diarrhées aiguës du nourrisson , 1997 .

[20]  L. Moulton,et al.  Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. , 1997, The Journal of pediatrics.

[21]  X. Pang,et al.  Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis , 1997, The Lancet.

[22]  A. Kapikian,et al.  Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. , 1997, The New England journal of medicine.

[23]  T. Vesikari,et al.  Prolonged efficacy of rhesus-human reassortant rotavirus vaccine. , 1998, The Pediatric infectious disease journal.

[24]  M. Mäkelä,et al.  Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  P. Wright,et al.  Epidemiology of rotavirus in infants and protection against symptomatic illness afforded by primary infection and vaccination. , 1999, Vaccine.

[26]  B. Grandbastien,et al.  [Impact of an information campaign on the prescription of ambulatory oral rehydration solutions in infants with acute gastroenteritis]. , 2000, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[27]  B. Schwartz,et al.  Intussusception among infants given an oral rotavirus vaccine. , 2001, The New England journal of medicine.

[28]  D. Feeny,et al.  The Health Utilities Index (HUI®) system for assessing health-related quality of life in clinical studies , 2001, Annals of medicine.

[29]  D. Gendrel,et al.  Hospitalisations pour gastroentrites aigus communautaires rotavirus: une enqute de quatre ans , 2002 .

[30]  E. Mallet,et al.  Epidemiology of acute viral gastroenteritis in children hospitalized in Rouen, France. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  A. Flahault,et al.  Virus Diversity in a Winter Epidemic of Acute Diarrhea in France , 2002, Journal of Clinical Microbiology.

[32]  F. Fourquet,et al.  Le poids médico-économique des gastro-entérites aiguës de l’enfant : l’éclairage du Programme de Médicalisation des Systèmes d’Information (PMSI)☆ , 2003 .

[33]  Mark A. Miller,et al.  Global Illness and Deaths Caused by Rotavirus Disease in Children , 2003, Emerging infectious diseases.

[34]  T. Vesikari,et al.  A Rotavirus Vaccine for Prophylaxis of Infants Against Rotavirus Gastroenteritis , 2004, The Pediatric infectious disease journal.

[35]  Y. Yazdanpanah,et al.  Morbidité et coût des infections à rotavirus en France , 2005 .

[36]  A. Linhares,et al.  Evaluation of Safety, Immunogenicity and Efficacy of an Attenuated Rotavirus Vaccine, RIX4414: A Randomized, Placebo-Controlled Trial in Latin American Infants , 2005, The Pediatric infectious disease journal.

[37]  B. Dervaux,et al.  The economic value of childhood varicella vaccination in France and Germany. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[38]  R. Glass,et al.  Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. , 2005, The Journal of infectious diseases.

[39]  J. Heyse,et al.  Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. , 2006, The New England journal of medicine.

[40]  C. Giaquinto,et al.  Economics of Rotavirus Gastroenteritis and Vaccination in Europe: What Makes Sense? , 2006, The Pediatric infectious disease journal.

[41]  R. Glass,et al.  Rotavirus vaccines: current prospects and future challenges , 2006, The Lancet.

[42]  T. Vesikari,et al.  Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. , 2006, The New England journal of medicine.

[43]  Y. Yazdanpanah,et al.  Effectiveness of childhood vaccination against rotavirus in sub-Saharan Africa: the case of Nigeria. , 2007, Vaccine.

[44]  R. Glass,et al.  Cost-effectiveness and Potential Impact of Rotavirus Vaccination in the United States , 2007, Pediatrics.

[45]  M. Jit,et al.  Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. , 2007, Vaccine.